These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38759575)

  • 1. Outpatient management of Post-COVID syndrome - single center experience.
    Torres F; Shedd C; Kaza V; Bollineni S; Banga A; Mohanka MR; Ladikos N; Wijesinha M; Mahan LD; Lawrence A; Joerns J; Terada L; Timofte I
    Heart Lung; 2024; 67():137-143. PubMed ID: 38759575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-COVID Interstitial Lung Disease: How do We Deal with This New Entity?
    Yüksel A; Karadoğan D; Hürsoy N; Telatar TG; Köse Kabil N; Marım F; Kaya İ; Er AB; Erçelik M; Polat Yuluğ D; Yumrukuz Şenel M; İlgar C; Gültekin Ö; Çakmakcı Karakaya S; Yılmaz Kara B; Özçelik N; Selimoğlu İ; Uyar Er K; Kotan A; Veysel Keskin H; Akgün M
    Balkan Med J; 2024 Sep; 41(5):377-386. PubMed ID: 39192585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Complaints and clinical findings six months after COVID-19: outpatient follow-up at the University Medical Center Freiburg].
    August D; Stete K; Hilger H; Götz V; Biever P; Hosp J; Wagner D; Köhler TC; Gerstacker K; Seufert J; Laubner K; Kern W; Rieg S
    Dtsch Med Wochenschr; 2021 Sep; 146(17):e65-e73. PubMed ID: 34425627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
    Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
    Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.
    Myall KJ; Mukherjee B; Castanheira AM; Lam JL; Benedetti G; Mak SM; Preston R; Thillai M; Dewar A; Molyneaux PL; West AG
    Ann Am Thorac Soc; 2021 May; 18(5):799-806. PubMed ID: 33433263
    [No Abstract]   [Full Text] [Related]  

  • 6. Protracted respiratory findings in children post-SARS-CoV-2 infection.
    Leftin Dobkin SC; Collaco JM; McGrath-Morrow SA
    Pediatr Pulmonol; 2021 Dec; 56(12):3682-3687. PubMed ID: 34534416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic.
    Shao C; Shi Y; Chen R; Liu X; Huang H; Zhao Y; Xu K; Chen K; Wang M; Xu Z
    J Med Virol; 2023 Sep; 95(9):e29098. PubMed ID: 37707416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
    Fischer A; Brown KK; Du Bois RM; Frankel SK; Cosgrove GP; Fernandez-Perez ER; Huie TJ; Krishnamoorthy M; Meehan RT; Olson AL; Solomon JJ; Swigris JJ
    J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term pulmonary sequelae in adolescents post-SARS-CoV-2 infection.
    Palacios S; Krivchenia K; Eisner M; Young B; Ramilo O; Mejias A; Lee S; Kopp BT
    Pediatr Pulmonol; 2022 Oct; 57(10):2455-2463. PubMed ID: 35775163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease.
    Fesu D; Polivka L; Barczi E; Foldesi M; Horvath G; Hidvegi E; Bohacs A; Muller V
    Inflammopharmacology; 2023 Apr; 31(2):565-571. PubMed ID: 36961666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease.
    Ramadurai D; Riordan M; Graney B; Churney T; Olson AL; Swigris JJ
    Respir Med; 2018 May; 138():32-37. PubMed ID: 29724390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review.
    Xia J; Jiang G; Jin T; Shen Q; Ma Y; Wang L; Qian L
    BMC Pediatr; 2021 Nov; 21(1):488. PubMed ID: 34732158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
    Chartrand S; Swigris JJ; Peykova L; Fischer A
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Concise Review 2020: Interstitial lung disease.
    Teoh AKY; Corte TJ
    Respirology; 2021 Jun; 26(6):604-611. PubMed ID: 33913200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary testing in long COVID-19 versus non-COVID-19 patients with undifferentiated Dyspnea on exertion.
    Contreras AM; Newman DB; Cappelloni L; Niven AS; Mueller MR; Ganesh R; Squires RW; Bonikowske AR; Allison TG
    Prog Cardiovasc Dis; 2024; 83():71-76. PubMed ID: 37211198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease.
    Bevanda L; Mok V; Lin K; Assayag D; Fisher JH; Johannson KA; Khalil N; Kolb M; Manganas H; Marcoux V; Sadatsafavi M; Wong AW; Ryerson CJ
    Ann Am Thorac Soc; 2024 Jul; 21(7):1007-1014. PubMed ID: 38315632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.